CD47 and neoplasm: One promising approach for TAMs-targeted combination therapy is the use of oncolytic HSV-1 expressing a full-length anti-human CD47 IgG1, which blocks the CD47 “don’t eat me” signal expressed on the surface of tumor cells, enhancing the phagocytosis of tumor cells by macrophages and improving the tumor-killing effect of OV therapy (Xu et al., 2021).